FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108331987> ?p ?o ?g. }

• W2108331987 endingPage "418" @default.
• W2108331987 startingPage "410" @default.
• W2108331987 abstract "Abstract Oral premalignancy serves as an ideal model for study of chemopreventive agents. Although 13-cis-retinoic acid showed reversal of oral premalignancy, toxicity, and reversal of clinical response after cessation of therapy obviated its widespread use. A search for nontoxic agents with cancer preventive activity led us to evaluate Bowman Birk Inhibitor (BBI) formulated as BBI Concentrate (BBIC). We previously reported encouraging results in a phase IIa trial of BBIC in patients with oral leukoplakia with measurable clinical responses and favorable biomarker changes. On the basis of these results, we undertook a randomized, placebo controlled phase IIb trial with patients receiving BBIC or placebo for 6 months, with assessment of clinical response and change in lesion area as primary end point and an intent-to-treat analysis. One hundred and thirty two subjects were randomized; and 89 subjects completed six months on study drug or placebo. Both placebo and BBIC showed a statistically significant decrease in mean lesion area of 17.1% and 20.6%, respectively, and partial or greater clinical responses of 30% and 28% respectively. No significant difference between placebo and study drug arms was observed. Histologic review, review of photographs of lesions, and comparison of serum neu protein and oral mucosal cell protease activity also did not show significant differences between study arms. Probable reasons for these negative results were considered, are discussed, and include a placebo with non-BBIC clinical activity and reduced pharmacokinetic availability of the second batch of BBIC. This experience should be a strong cautionary note to those considering “Green” chemoprevention. Cancer Prev Res; 6(5); 410–8. ©2013 AACR." @default.
• W2108331987 created "2016-06-24" @default.
• W2108331987 creator A5008515664 @default.
• W2108331987 creator A5015536826 @default.
• W2108331987 creator A5018753315 @default.
• W2108331987 creator A5026698479 @default.
• W2108331987 creator A5035667571 @default.
• W2108331987 creator A5038403506 @default.
• W2108331987 creator A5059503850 @default.
• W2108331987 creator A5060872059 @default.
• W2108331987 creator A5064894255 @default.
• W2108331987 creator A5072249729 @default.
• W2108331987 creator A5072459165 @default.
• W2108331987 creator A5073549934 @default.
• W2108331987 creator A5075478892 @default.
• W2108331987 date "2013-05-01" @default.
• W2108331987 modified "2023-10-15" @default.
• W2108331987 title "Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial" @default.
• W2108331987 cites W1969010440 @default.
• W2108331987 cites W1986850330 @default.
• W2108331987 cites W1994836178 @default.
• W2108331987 cites W1998890155 @default.
• W2108331987 cites W1999243658 @default.
• W2108331987 cites W2001311961 @default.
• W2108331987 cites W2004636370 @default.
• W2108331987 cites W2010601911 @default.
• W2108331987 cites W2010716380 @default.
• W2108331987 cites W2014646550 @default.
• W2108331987 cites W2017896553 @default.
• W2108331987 cites W2036654669 @default.
• W2108331987 cites W2049506505 @default.
• W2108331987 cites W2053416121 @default.
• W2108331987 cites W2072031500 @default.
• W2108331987 cites W2077778212 @default.
• W2108331987 cites W2106202763 @default.
• W2108331987 cites W2136888303 @default.
• W2108331987 cites W2171389927 @default.
• W2108331987 cites W2199607744 @default.
• W2108331987 doi "https://doi.org/10.1158/1940-6207.capr-13-0004" @default.
• W2108331987 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3730525" @default.
• W2108331987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23639862" @default.
• W2108331987 hasPublicationYear "2013" @default.
• W2108331987 type Work @default.
• W2108331987 sameAs 2108331987 @default.
• W2108331987 citedByCount "53" @default.
• W2108331987 countsByYear W21083319872013 @default.
• W2108331987 countsByYear W21083319872014 @default.
• W2108331987 countsByYear W21083319872015 @default.
• W2108331987 countsByYear W21083319872016 @default.
• W2108331987 countsByYear W21083319872017 @default.
• W2108331987 countsByYear W21083319872018 @default.
• W2108331987 countsByYear W21083319872019 @default.
• W2108331987 countsByYear W21083319872020 @default.
• W2108331987 countsByYear W21083319872021 @default.
• W2108331987 countsByYear W21083319872022 @default.
• W2108331987 countsByYear W21083319872023 @default.
• W2108331987 crossrefType "journal-article" @default.
• W2108331987 hasAuthorship W2108331987A5008515664 @default.
• W2108331987 hasAuthorship W2108331987A5015536826 @default.
• W2108331987 hasAuthorship W2108331987A5018753315 @default.
• W2108331987 hasAuthorship W2108331987A5026698479 @default.
• W2108331987 hasAuthorship W2108331987A5035667571 @default.
• W2108331987 hasAuthorship W2108331987A5038403506 @default.
• W2108331987 hasAuthorship W2108331987A5059503850 @default.
• W2108331987 hasAuthorship W2108331987A5060872059 @default.
• W2108331987 hasAuthorship W2108331987A5064894255 @default.
• W2108331987 hasAuthorship W2108331987A5072249729 @default.
• W2108331987 hasAuthorship W2108331987A5072459165 @default.
• W2108331987 hasAuthorship W2108331987A5073549934 @default.
• W2108331987 hasAuthorship W2108331987A5075478892 @default.
• W2108331987 hasBestOaLocation W21083319871 @default.
• W2108331987 hasConcept C112705442 @default.
• W2108331987 hasConcept C121608353 @default.
• W2108331987 hasConcept C126322002 @default.
• W2108331987 hasConcept C141071460 @default.
• W2108331987 hasConcept C142724271 @default.
• W2108331987 hasConcept C143998085 @default.
• W2108331987 hasConcept C168563851 @default.
• W2108331987 hasConcept C185592680 @default.
• W2108331987 hasConcept C203092338 @default.
• W2108331987 hasConcept C204787440 @default.
• W2108331987 hasConcept C27081682 @default.
• W2108331987 hasConcept C2777550702 @default.
• W2108331987 hasConcept C2781156865 @default.
• W2108331987 hasConcept C2781197716 @default.
• W2108331987 hasConcept C535046627 @default.
• W2108331987 hasConcept C55493867 @default.
• W2108331987 hasConcept C71924100 @default.
• W2108331987 hasConcept C90924648 @default.
• W2108331987 hasConceptScore W2108331987C112705442 @default.
• W2108331987 hasConceptScore W2108331987C121608353 @default.
• W2108331987 hasConceptScore W2108331987C126322002 @default.
• W2108331987 hasConceptScore W2108331987C141071460 @default.
• W2108331987 hasConceptScore W2108331987C142724271 @default.
• W2108331987 hasConceptScore W2108331987C143998085 @default.
• W2108331987 hasConceptScore W2108331987C168563851 @default.
• W2108331987 hasConceptScore W2108331987C185592680 @default.
• W2108331987 hasConceptScore W2108331987C203092338 @default.

• next